These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37909092)

  • 1. Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers.
    Mulvaney KM
    Cancer Discov; 2023 Nov; 13(11):2310-2312. PubMed ID: 37909092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
    Engstrom LD; Aranda R; Waters L; Moya K; Bowcut V; Vegar L; Trinh D; Hebbert A; Smith CR; Kulyk S; Lawson JD; He L; Hover LD; Fernandez-Banet J; Hallin J; Vanderpool D; Briere DM; Blaj A; Marx MA; Rodon J; Offin M; Arbour KC; Johnson ML; Kwiatkowski DJ; Jänne PA; Haddox CL; Papadopoulos KP; Henry JT; Leventakos K; Christensen JG; Shazer R; Olson P
    Cancer Discov; 2023 Nov; 13(11):2412-2431. PubMed ID: 37552839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
    Barbarino M; Cesari D; Bottaro M; Luzzi L; Namagerdi A; Bertolino FM; Bellan C; Proietti F; Somma P; Micheli M; de Santi MM; Guazzo R; Mutti L; Pirtoli L; Paladini P; Indovina P; Giordano A
    J Cell Mol Med; 2020 May; 24(10):5565-5577. PubMed ID: 32301278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
    Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
    J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
    Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
    Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors.
    Chen S; Hou J; Jaffery R; Guerrero A; Fu R; Shi L; Zheng N; Bohat R; Egan NA; Yu C; Sharif S; Lu Y; He W; Wang S; Gjuka D; Stone EM; Shah PA; Rodon Ahnert J; Chen T; Liu X; Bedford MT; Xu H; Peng W
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with
    Cottrell KM; Briggs KJ; Whittington DA; Jahic H; Ali JA; Davis CB; Gong S; Gotur D; Gu L; McCarren P; Tonini MR; Tsai A; Wilker EW; Yuan H; Zhang M; Zhang W; Huang A; Maxwell JP
    J Med Chem; 2024 Apr; 67(8):6064-6080. PubMed ID: 38595098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
    Rodon J; Prenen H; Sacher A; Villalona-Calero M; Penel N; El Helali A; Rottey S; Yamamoto N; Ghiringhelli F; Goebeler ME; Doi T; Postel-Vinay S; Lin CC; Liu C; Chuang CH; Keyvanjah K; Eggert T; O'Neil BH
    Ann Oncol; 2024 Dec; 35(12):1138-1147. PubMed ID: 39293516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
    Smith CR; Aranda R; Christensen JG; Engstrom LD; Gunn RJ; Ivetac A; Ketcham JM; Kuehler J; David Lawson J; Marx MA; Olson P; Thomas NC; Wang X; Waters LM; Kulyk S
    Bioorg Med Chem; 2022 Oct; 71():116947. PubMed ID: 35926325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers.
    Belmontes B; Slemmons KK; Su C; Liu S; Policheni AN; Moriguchi J; Tan H; Xie F; Aiello DA; Yang Y; Lazaro R; Aeffner F; Rees MG; Ronan MM; Roth JA; Vestergaard M; Cowland S; Andersson J; Sarvary I; Chen Q; Sharma P; Lopez P; Tamayo N; Pettus LH; Ghimire-Rijal S; Mukund S; Allen JR; DeVoss J; Coxon A; Rodon J; Ghiringhelli F; Penel N; Prenen H; Glad S; Chuang CH; Keyvanjah K; Townsley DM; Butler JR; Bourbeau MP; Caenepeel S; Hughes PE
    Cancer Discov; 2024 Sep; ():. PubMed ID: 39282709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM; Bartlett DL; Cieply K; Dacic S
    Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
    Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
    J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance.
    Gjuka D; Adib E; Garrison K; Chen J; Zhang Y; Li W; Boutz D; Lamb C; Tanno Y; Nassar A; El Zarif T; Kale N; Rakaee M; Mouhieddine TH; Alaiwi SA; Gusev A; Rogers T; Gao J; Georgiou G; Kwiatkowski DJ; Stone E
    Cancer Cell; 2023 Oct; 41(10):1774-1787.e9. PubMed ID: 37774699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.